(NASDAQ: EQ) Equillium's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.
Equillium's earnings in 2025 is -$24,417,000.On average, 6 Wall Street analysts forecast EQ's earnings for 2025 to be -$46,729,505, with the lowest EQ earnings forecast at -$62,659,188, and the highest EQ earnings forecast at -$28,132,697. On average, 6 Wall Street analysts forecast EQ's earnings for 2026 to be -$42,966,300, with the lowest EQ earnings forecast at -$67,433,222, and the highest EQ earnings forecast at -$15,345,107.
In 2027, EQ is forecast to generate -$13,798,418 in earnings, with the lowest earnings forecast at -$13,128,592 and the highest earnings forecast at -$14,066,348.